Galectin Converts $105.8M in Debt to Equity
Chairman Richard E. Uihlein converted $105.8 million in outstanding debt into 34.4 million common shares, significantly strengthening the biopharmaceutical company's balance sheet.
View filing at SEC.gov →2 most recent filings and news items mentioning GALT. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/GALT/news?limit=20"
Pull GALT filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayChairman Richard E. Uihlein converted $105.8 million in outstanding debt into 34.4 million common shares, significantly strengthening the biopharmaceutical company's balance sheet.
View filing at SEC.gov →Galectin Therapeutics reached an agreement with the FDA on the primary endpoint and regulatory pathway for belapectin in MASH cirrhosis patients. This alignment clarifies the Phase 3 protocol and supports the company's evaluation of strategic partnerships to support development.
View filing at SEC.gov →